A Phase 2 interventional study of Givinostat and Placebo in Becker Muscular Dystrophy, sponsored by Italfarmaco. Completed at 2 sites in 2 countries. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-18.
Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Muscular Dystrophy, Duchenne with a site in Italy — 19 open to participants now, 26 under way, 7 of them phase 3. Muscular Dystrophy, Duchenne · Italy.
Among the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy, this one is the 41st largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 20 in phase 2, and was the 38th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →19 of the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Italy, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Istituto Giannina Gaslini · Sites in Italy
Ages 18+ · Men only
Entrada Therapeutics, Inc. · Sites in Italy, Belgium, Netherlands and 2 more countries
Ages 4–20 · Men only
Universita di Verona · Sites in Italy
Ages 16–65
Entrada Therapeutics, Inc. · Sites in Italy, Belgium, Spain and 1 more country
Ages 4–20 · Men only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 34 · Phase 3 27 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 73 across the 67 interventional studies, 225 across the 14 observational. Of the 51 that completed or were terminated, 29 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 82 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 8 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
6 of the studies in Muscular Dystrophy, Duchenne with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT06280209BioMarin PharmaceuticalA Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | 2027-04-14 |
| NCT06138639Solid Biosciences Inc.A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | 2027-05-06 |
| NCT07101185IRCCS Eugenio MedeaTransition to Adulthood in People With Muscular Dystrophy | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives:
Primary objective: to establish the histological effects of Givinostat versus placebo administered over 12 months.
Secondary Objectives:
This was a phase 2, randomised, double-blind, placebo-controlled study. Eligible patients were randomized in a 2:1 ratio to receive Givinostat or placebo for 12 months. Randomization was stratified by concomitant steroid use at baseline (yes or no). The study comprised twelve (12) visits: screening (V1, V2), randomization (V3), treatment (V4-V10), end of study (V11) and follow-up (V12). Visits during treatment took place every 12 weeks, except for the first 2 months, when they occurred every 2 weeks to allow closer monitoring of safety.
Givinostat (ITF2357) oral suspension (10 mg/mL) was initially administered as 2 daily doses of 40-70 mg according to body weight after a meal (high dose). With amendment 2 of the protocol, a lower starting dose was implemented to address cases of thrombocytopenia reported following the treatment of the first 21 patients and corresponded to the reduced dose of the original protocol (i.e., 26.7-46.7 mg b.i.d according to body weight, i.e., low dose).
51 patients were to be enrolled to provide a sample size of 48 patients with evaluable baseline biopsies. Seventy patients provided written informed consent, 51 (72.86%) completed screening successfully and were randomized; 34 patients (66.67%) to the Givinostat group and 17 (33.33%) to the placebo group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients had to be willing to use adequate from randomization until 3 months after the last dose of study treatment, and included the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Givinostat oral suspension (10 mg/mL) twice daily in a fed state
Drug: Givinostat
Placebo oral suspension (10 mg/mL) twice daily in a fed state
Drug: Placebo
suspension of Givinostat (10 mg/mL)
Also known as: ITF2357
suspension manufactured to mimic Givinostat
Also known as: Placebo Comparator: placebo
Mean Change From Baseline to Visit 11 in Total Fibrosis (%) on Log Scale, Comparing the Histology of Muscle Biopsies
The primary efficacy assessment was the mean total fibrosis (%) on log scale assessed through histological examination of bicep muscle biopsies at two timepoints (At baseline and at Visit 11). More particularly, patients underwent two biopsies of muscle from the brachial biceps: the first before starting the study treatment (Visit 2, baseline), and the second at the end of treatment (Visit 11). For each patient, the percentage of total fibrosis was calculated as log of the least square mean of the available fields at each evaluation.
Time frame: after 12 months of treatment (at Visit 11)
Mean Change From Baseline to Visit 11 in the Percentage of Fat Fraction of Vastus Lateralis and Soleus
Evaluation was performed comparing Magnetic Resonance Spectroscopy (MRS) before and after 12 months of treatment with Givinostat versus placebo. Please note that Statistics data are expressed as log least square mean (IC 95%) for the vastus lateralis and as least square mean (IC 95%) back-transformed on the original scale for the soleus.
Time frame: after 12 months of treatment (at Visit 11)
Mean Change From Baseline to Visit 11 in the Percentage of Fat Fraction of Lower Limb Muscles
Evaluation was performed comparing Dixon Magnetic Resonance Imaging (MRI) before and after 12 months of treatment with Givinostat versus placebo. The lower limb muscles assessed were: whole thigh, quadriceps, medial thigh, hamstrings, triceps surae and pelvic girdle. Please note that statistics data are expressed as: Least Square Means (95% CI) for whole thigh, quadriceps, hamstrings, triceps surae and pelvis girdle; while as Log Least Square Means (95% CI) for medial thigh.
Time frame: after 12 months of treatment (at Visit 11)
Mean Change From Baseline to Visit 11 in Cross-sectional Area (CSA), in cm2 of Lower Limb Muscles
Evaluation was performed comparing Dixon MRI findings before and after 12 months of treatment with Givinostat versus placebo. Dixon technique has advantages in multiple applications for evaluation of musculoskeletal system diseases. It allows more robust fat suppression than do other sequences and can be used in combination with multiple different sequences (GRE and SE) and using different weightings (T1, T2, or proton density). The lower limb muscles assessed were: whole thigh, quadriceps, medial thigh, hamstrings, triceps surae and pelvic girdle (data showed as least square mean)
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Contractile Area of Lower Limb Muscles (MRI)
A summary of mean change in the contractile area of lower limb muscles comparing MRI findings before and after 12 months of treatment in the ITT set is reported. The lower limb muscles considered are the same as the outcome 3. Please note that statistic data are expressed as Least Square Means (95% CI) except for Hamstrings which is expressed as Log Least Square Means.
Time frame: after 12 months of treatment
Mean Change From Baseline to Visit 11 in Biopsy Histology Parameters: CSA by Type (I or II Fibers), Total CSA
A summary of the mean change in cross-sectional area (CSA) by type after 12 months of treatment in the ITT set is reported. Please note that descriptive statistic data are expressed as Log Least Square Means (95% CI) for CSA type I fibers, and as Least Square Means (95% CI) for CSA type II fibers and Total CSA.
Time frame: After 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Percentage for the Following Histology Parameters: Fibers With Nuclear Centralizations (%), Total Number of Fibers (%), Regenerative Fibers (%).
Evaluation of histologic parameters such as Fiber with nuclear centralizations (%), Total number of fibers (%), and Regenerative fibers (%) were performed comparing muscle biopsies after 12 months of treatment with Givinostat. Please note that descriptive statistic data are expressed as log least square mean for Regenerative fibers (%), and total number of fibers (Slides I), while are expressed as least square mean for Fibers with nuclear centralizations (%) and total number of fibers (Slides II and III).
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Percentage for the Biopsy Histology Parameter MFA(%)
Evaluation of histology parameters such as Muscle Fibers Area \[MFA\](%), were performed comparing muscle biopsies after 12 months of treatment with Givinostat. MFA fraction was determined from biopsies using the mean of available fields. Please note that descriptive statistic data are expressed as least square mean.
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Percentage for the Biopsy Histology Parameters Adipose Tissue (%)
Evaluation of histology parameters such as Adipose tissue (%) were performed comparing muscle biopsies after 12 months of treatment with Givinostat. Please note that descriptive statistic data are expressed as log least square mean.
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Other Histological Structures
Evaluation of other histological structures like necrotic cells, vessels and any other nonconnective tissue present in the microscopic field were performed comparing muscle biopsies after 12 months of treatment with Givinostat. The value is shown as % compared to the arithmetic mean of the two positive control (i.e., healthy subjects) bands present in the same western blot. Please note that descriptive statistic data are expressed as log least square mean.
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Motor Function Measurement (MFM, Expressed as Log Least Square Mean)
Evaluation were performed using the MFM32 scale, that is a tool designed for neuromuscular diseases and is applicable to all degrees of disease severity. It was validated in terms of reproducibility, construct validity, and concurrent validity. It consists of 32 items (tasks) classified into three dimensions: D1, standing and transfers; D2, axial and proximal motor capacity; and D3, distal motor capacity. Each item is scored on a four-point Likert scale. The generic grading is measured as follows: 0, cannot initiate the task or cannot maintain the starting position; 1, partially performs the task; 2, performs the task with compensatory movements (position maintained for an insufficient period of time, slowness, uncontrolled movements, etc.); and 3, performs the task fully and 'normally', the movement being controlled, mastered, directed, and performed at a constant speed. The overall total score ranging from 0 (severe functional impairment) to 100 (no functional impairment).
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Time Function Test (TFT): Time to Walk/Run 10 Meters
TFT is assessed through 3 different parameters one of which is time to walk/run 10 m. The test was performed with or without orthoses as the patient preferred. He/she was not asked to run, but rather to arrive at the finish line as soon as possible leaving him the choice on how to do so. The assessor walked alongside the patient for safety but couldn't help her/him in any way. The walk/run speed was calculated as 10/time in seconds taken to run/walk 10 m. The test was graded as follows: 1. Unable to walk independently. 2. Unable to walk independently but can walk with full leg calipers (KAFOs) or with support of a person. 3. Highly adapted wide-based lordotic gait. Can't increase walking speed. 4. Moderately adapted gait. Can pick up speed but can't run. 5. Able to pick up speed but runs with a double stance phase, i.e., cannot achieve both feet off the ground. 6. Runs and gets both feet off the ground (with no double stance phase). The higher the grade, the better the outcome.
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Time Function Test (TFT) Via Time to Climb 4 Standard Steps
TFT is assessed through 3 parameters, one of which is "time to climb 4 standard steps". The patient was asked to stand at the bottom of the stairs with his arms by his sides. At the "go" signal, he/she had to walk up the stairs as quickly and safely as possible (using handrails if needed) until reaching an erect position on the top stair. The stair climb speed was calculated as 4/time in seconds taken to climb the 4 standard stairs. Grading of the 4-step ascent was:1. Unable to climb 4 stairs.2. Climbs 4 stairs "marking time" (climbs one foot at a time with both feet on a step before moving to next step), using both arms on one or both handrails.3. Climbs 4 stairs "marking time" (idem as up), using one arm on one handrail.4. Climbs 4 stairs "marking time" (idem as up), not needing handrail.5. Climbs 4 stairs alternating feet, needs handrail for support.6. Climbs 4 stairs alternating feet, not needing handrail support.The higher the grade, the better the outcome.
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Time Function Test Via Time to Rise From Floor
Time function test (TFT) is assessed through 3 different parameters, one of which was "time to rise from the floor". The patient started the test lying on his back with arms at his sides and was asked to get up as quickly as possible. The rise from floor velocity was calculated as 1/time in seconds taken to stand up. Grading was as follows: 1. Unable to stand, even with use of a chair. 2. Assisted Gowers' sign - requires furniture to assist in rising to full upright posture. 3. Full Gowers' sign - rolls over, stands up with both hands "climbing up" the legs to achieve full upright posture. 4. Half Gowers' sign - rolls over, stands up with one hand support on leg. 5. Rolls to the side and/or stands up with one hand or both hands on the floor to start to rise up but does not touch legs. 6. Stands up without rolling over or using hands. The higher the grade, the better the outcome.
Time frame: after 12 months of treatment (Visit 11)
Change From Baseline to Visit 11 in Distance Performed Via 6-minute Walk/Run Test (6MWT, Expressed as Log Least Square Mean)
The 6-minute walk/run test (6MWT) assessed the distance walked in 6 minutes. The 6MWT was performed indoors on a flat, smooth path, at least 30 m long and 3 m wide, with a cone at each end around which the patient had to walk. Six progressively numbered markers were used to mark the distance travelled at each minute. Five progressively lettered markers were used to indicate any falls. Two staff members were present during the test; the physiotherapist, to give the patient instructions, and a staff member who followed the patient giving encouragements. The patient was instructed to go from cone to cone as fast as he could but without running, and that he could stop to rest whenever he/she wanted. The time walked, distance walked after each minute, time of each fall and distance walked before each fall were registered. A summary of the 6-minute maximum distance walked/run after 12 months of treatment is reported in minutes.
Time frame: after 12 months of treatment (Visit 11)
Percentage of Patients With < 10% Worsening in 6MWT After 12 Months of Treatment.
Percentage of patients with \< 10% worsening in 6-Minute Walking Test after 12 months of treatment with Givinostat comparing to placebo patients.
Time frame: after 12 months of treatment (Visit 11)
Count of Participant Who Lose Ambulation During the Study (From Baseline to Month 12)
Percentage of patients losing the ability to ambulate from baseline to the end of study (Visit 11 or Month 12)
Time frame: from baseline to the end of month 12
Percentage of Patients Who Fell During the 6MWT
A summary of the number of patients who fell and the number of falls occurring during the 6MWT is shown.
Time frame: after 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Muscle Strength Evaluated by Knee Extension, Elbow Flexion
Evaluation was performed by mean left and right knee extension, mean left and right elbow flexion using the Hand Held Myometry (HHM). Using it, the muscle strength of the knee extensor and elbow flexor were measured via standardized procedures; 3 measurements were recorded from each muscle group on each side. The mean of the 3 measurements was calculated. Knee Extension: the pt was sitting, pelvis and knee at a 90° angle. His/her feet were above the ground with the femur in neutral rotation. He/she could hold on to the edge of the bed/chair and, in case, additional stabilization was provided at the distal third of the thigh, just above the knee. The HHM was placed on the anterior surface of the lower third of the tibia, proximal to the ankle joint. Elbow flexion: pt lying on his back, arm by his side, elbow flexed at a 90° angle, forearm in supine position. The MMH was placed between the middle and distal third of the forearm, proximal to the radial styloid process.
Time frame: after 12 months of treatment (Visit 11)
Mean Changes From Baseline to Visit 11 in Quality of Life (QoL, Assessed by the 36-item Short Form Survey [SF36])
A summary of QoL (SF-36, Single items Short Form survey) in the ITT set is shown. QoL (SF-36) is assessed considering: * Physical Functioning (PF) * Role-Physical (RP) * Bodily Pain (BP) * General Health (GH) * Vitality (VT) * Social Functioning (SF) * Role-Emotional (RE) * Mental Health (MH) * Physical Component Summary (PCS) * Mental Component Summary (MCS) The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score, the greater the disability. The SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and are widely utilized by managed care organizations for routine monitoring and assessment of care outcomes in adult patients.
Time frame: after 12 months of treatment (Visit 11)
Number of Patients Experiencing Any Kind of Severity of TEAEs, Serious and Non Serious) From Baseline Through End of Study (EOS).
Treatment-emergent adverse events (TEAEs) are defined as those events with an onset date after study treatment initiation. An AE is an untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. A serious AE is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
Time frame: Throughout the study, till week 52 +/-7 days
Mean Change From Baseline to Visit 11 in the Percentage of Fat Fraction of Lower Limb Muscles (Log)
Evaluation was performed comparing Dixon Magnetic Resonance Imaging (MRI) before and after 12 months of treatment with Givinostat versus placebo. The lower limb muscles assessed were: whole thigh, quadriceps, medial thigh, hamstrings, triceps surae and pelvic girdle. Please note that statistics data are expressed as: Least Square Means (95% CI) for whole thigh, quadriceps, hamstrings, triceps surae and pelvis girdle; while as Log Least Square Means (95% CI) for medial thigh.
Time frame: after 12 months of treatment (at Visit 11)
Mean Change From Baseline to Visit 11 in Contractile Area of Lower Limb Muscles (MRI) (Log)
A summary of mean change in the contractile area of lower limb muscles comparing MRI findings before and after 12 months of treatment in the ITT set is reported. The lower limb muscles considered are the same as the outcome 3. Please note that statistic data are expressed as Least Square Means (95% CI) except for Hamstrings which is expressed as Log Least Square Means.
Time frame: after 12 months of treatment
Mean Change From Baseline to Visit 11 in Biopsy Histology Parameters: CSA by Type (I or II Fibers), Total CSA (Log)
A summary of the mean change in cross-sectional area (CSA) by type after 12 months of treatment in the ITT set is reported. Please note that descriptive statistic data are expressed as Log Least Square Means (95% CI) for CSA type I fibers, and as Least Square Means (95% CI) for CSA type II fibers and Total CSA.
Time frame: After 12 months of treatment (Visit 11)
Mean Change From Baseline to Visit 11 in Percentage for the Following Histology Parameters: Fibers With Nuclear Centralizations (%), Total Number of Fibers (%), Regenerative Fibers (%). (Log)
Evaluation of histologic parameters such as Fiber with nuclear centralizations (%), Total number of fibers (%), and Regenerative fibers (%) were performed comparing muscle biopsies after 12 months of treatment with Givinostat. Please note that descriptive statistic data are expressed as log least square mean for Regenerative fibers (%), and total number of fibers (Slides I), while are expressed as least square mean for Fibers with nuclear centralizations (%) and total number of fibers (Slides II and III).
Time frame: after 12 months of treatment (Visit 11)
Seventy patients provided written informed consent to participate in this study. Fifty-one patients (72.86%) completed screening successfully and were randomized; 34 patients (66.67%) were assigned to the Givinostat group and 17 (33.33%) to the placebo group.
| Milestone | Givinostat | Placebo |
|---|---|---|
| Started | 34 | 17 |
| Per protocol | 25 | 14 |
| Itt | 34 | 17 |
| Safety | 34 | 17 |
| Pk | 34 | 17 |
| Completed | 30 | 17 |
| Not completed | 4 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Patients unable to travel to the site due to the covid-19 pandemic | 2 | 0 |
The primary efficacy assessment was the mean total fibrosis (%) on log scale assessed through histological examination of bicep muscle biopsies at two timepoints (At baseline and at Visit 11). More particularly, patients underwent two biopsies of muscle from the brachial biceps: the first before starting the study treatment (Visit 2, baseline), and the second at the end of treatment (Visit 11). For each patient, the percentage of total fibrosis was calculated as log of the least square mean of the available fields at each evaluation.
| log[percentage of total fibrosis] | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Total Fibrosis (%) on Log Scale, Comparing the Histology of Muscle Biopsies | -0.017 (-0.367 to 0.333) | -0.054 (-0.507 to 0.399) |
Evaluation was performed comparing Magnetic Resonance Spectroscopy (MRS) before and after 12 months of treatment with Givinostat versus placebo. Please note that Statistics data are expressed as log least square mean (IC 95%) for the vastus lateralis and as least square mean (IC 95%) back-transformed on the original scale for the soleus.
| log[percentage of fat in muscle] | Givinostat | Placebo |
|---|---|---|
| Vastus Lateralis | 0.017 (-0.053 to 0.086) | 0.064 (-0.019 to 0.147) |
| Soleus | -4.287 (-6.126 to -2.447) | -4.021 (-6.404 to -1.637) |
Evaluation was performed comparing Dixon Magnetic Resonance Imaging (MRI) before and after 12 months of treatment with Givinostat versus placebo. The lower limb muscles assessed were: whole thigh, quadriceps, medial thigh, hamstrings, triceps surae and pelvic girdle. Please note that statistics data are expressed as: Least Square Means (95% CI) for whole thigh, quadriceps, hamstrings, triceps surae and pelvis girdle; while as Log Least Square Means (95% CI) for medial thigh.
| percentage of fat in muscle | Givinostat | Placebo |
|---|---|---|
| Whole Thigh | 0.642 (-0.328 to 1.611) | 1.996 (0.813 to 3.180) |
| Quadriceps | 0.610 (-0.506 to 1.726) | 2.572 (1.227 to 3.918) |
| Hamstrings | 0.877 (-0.627 to 2.381) | 1.455 (-0.400 to 3.309) |
| Triceps Surae | -0.276 (-2.862 to 2.310) | 1.317 (-1.686 to 4.319) |
| Pelvis Girdle | 0.584 (-0.509 to 1.676) | 1.471 (0.112 to 2.830) |
Evaluation was performed comparing Dixon MRI findings before and after 12 months of treatment with Givinostat versus placebo. Dixon technique has advantages in multiple applications for evaluation of musculoskeletal system diseases. It allows more robust fat suppression than do other sequences and can be used in combination with multiple different sequences (GRE and SE) and using different weightings (T1, T2, or proton density). The lower limb muscles assessed were: whole thigh, quadriceps, medial thigh, hamstrings, triceps surae and pelvic girdle (data showed as least square mean)
| centimeters^2 | Givinostat | Placebo |
|---|---|---|
| whole thigh | 2.782 (0.151 to 5.413) | 2.377 (-0.820 to 5.575) |
| quadriceps | 0.997 (-0.169 to 2.163) | 1.082 (-0.329 to 2.494) |
| medial thigh | 0.669 (-0.468 to 1.807) | 0.321 (-1.060 to 1.702) |
| hamstrings | 1.103 (0.108 to 2.098) | 0.994 (-0.207 to 2.195) |
| triceps surae | -0.033 (-3.699 to 3.634) | 0.183 (-3.756 to 4.122) |
| pelvic girdle | 1.284 (-0.494 to 3.062) | 0.965 (-1.187 to 3.116) |
A summary of mean change in the contractile area of lower limb muscles comparing MRI findings before and after 12 months of treatment in the ITT set is reported. The lower limb muscles considered are the same as the outcome 3. Please note that statistic data are expressed as Least Square Means (95% CI) except for Hamstrings which is expressed as Log Least Square Means.
| centimeters^2 | Givinostat | Placebo |
|---|---|---|
| Contractile Area in the Whole Thigh | 0.309 (-0.853 to 1.470) | -1.057 (-2.466 to 0.352) |
| Contractile Area in the Quadriceps | 0.139 (-0.458 to 0.735) | -0.493 (-1.195 to 0.210) |
| Contractile Area in the Medial Thigh | 0.162 (-0.342 to 0.665) | -0.197 (-0.813 to 0.420) |
| Contractile Area in the Triceps Surae | -0.542 (-3.598 to 2.514) | -1.291 (-4.632 to 2.050) |
| Contractile Area in the Pelvis Girdle | 0.257 (-0.420 to 0.933) | -0.287 (-1.133 to 0.559) |
A summary of the mean change in cross-sectional area (CSA) by type after 12 months of treatment in the ITT set is reported. Please note that descriptive statistic data are expressed as Log Least Square Means (95% CI) for CSA type I fibers, and as Least Square Means (95% CI) for CSA type II fibers and Total CSA.
| micrometers^2 | Givinostat | Placebo |
|---|---|---|
| CSA type II fibers | -25.320 (-1438.395 to 1387.755) | 593.875 (-1177.854 to 2365.604) |
| Total CSA | 642.505 (-603.081 to 1888.092) | 1215.047 (-359.764 to 2789.857) |
Evaluation of histologic parameters such as Fiber with nuclear centralizations (%), Total number of fibers (%), and Regenerative fibers (%) were performed comparing muscle biopsies after 12 months of treatment with Givinostat. Please note that descriptive statistic data are expressed as log least square mean for Regenerative fibers (%), and total number of fibers (Slides I), while are expressed as least square mean for Fibers with nuclear centralizations (%) and total number of fibers (Slides II and III).
| percentage of fibers | Givinostat | Placebo |
|---|---|---|
| Fibers with nuclear centralizations | 0.196 (-0.183 to 0.576) | 0.463 (0.006 to 0.921) |
| Total number of fibers (Slide II) | -24.573 (-59.132 to 9.986) | -22.346 (-64.799 to 20.106) |
| Total number of fibers (Slide III) | -9.804 (-22.511 to 2.904) | -14.521 (-30.335 to 1.293) |
Evaluation of histology parameters such as Muscle Fibers Area \[MFA\](%), were performed comparing muscle biopsies after 12 months of treatment with Givinostat. MFA fraction was determined from biopsies using the mean of available fields. Please note that descriptive statistic data are expressed as least square mean.
| percentage of muscle fiber area | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Percentage for the Biopsy Histology Parameter MFA(%) | 0.422 (-10.200 to 11.043) | -2.028 (-16.254 to 12.199) |
Evaluation of histology parameters such as Adipose tissue (%) were performed comparing muscle biopsies after 12 months of treatment with Givinostat. Please note that descriptive statistic data are expressed as log least square mean.
| percentage of total tissue | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Percentage for the Biopsy Histology Parameters Adipose Tissue (%) | 0.088 (-0.364 to 0.540) | 0.226 (-0.346 to 0.798) |
Evaluation of other histological structures like necrotic cells, vessels and any other nonconnective tissue present in the microscopic field were performed comparing muscle biopsies after 12 months of treatment with Givinostat. The value is shown as % compared to the arithmetic mean of the two positive control (i.e., healthy subjects) bands present in the same western blot. Please note that descriptive statistic data are expressed as log least square mean.
| percentage of total tissue | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Other Histological Structures | -0.297 (-0.832 to 0.238) | 0.045 (-0.611 to 0.701) |
Evaluation were performed using the MFM32 scale, that is a tool designed for neuromuscular diseases and is applicable to all degrees of disease severity. It was validated in terms of reproducibility, construct validity, and concurrent validity. It consists of 32 items (tasks) classified into three dimensions: D1, standing and transfers; D2, axial and proximal motor capacity; and D3, distal motor capacity. Each item is scored on a four-point Likert scale. The generic grading is measured as follows: 0, cannot initiate the task or cannot maintain the starting position; 1, partially performs the task; 2, performs the task with compensatory movements (position maintained for an insufficient period of time, slowness, uncontrolled movements, etc.); and 3, performs the task fully and 'normally', the movement being controlled, mastered, directed, and performed at a constant speed. The overall total score ranging from 0 (severe functional impairment) to 100 (no functional impairment).
| score on a scale | Givinostat | Placebo |
|---|---|---|
| Standing and transfers (D1) | -0.038 (-0.087 to 0.011) | -0.100 (-0.165 to -0.035) |
| Axial and proximal motor function (D2) | -0.004 (-0.012 to 0.004) | -0.007 (-0.018 to 0.003) |
| Distal motor function (D3) | -0.003 (-0.013 to 0.006) | -0.001 (-0.014 to 0.011) |
| Total Score | -0.011 (-0.025 to 0.002) | -0.026 (-0.044 to -0.008) |
TFT is assessed through 3 different parameters one of which is time to walk/run 10 m. The test was performed with or without orthoses as the patient preferred. He/she was not asked to run, but rather to arrive at the finish line as soon as possible leaving him the choice on how to do so. The assessor walked alongside the patient for safety but couldn't help her/him in any way. The walk/run speed was calculated as 10/time in seconds taken to run/walk 10 m. The test was graded as follows: 1. Unable to walk independently. 2. Unable to walk independently but can walk with full leg calipers (KAFOs) or with support of a person. 3. Highly adapted wide-based lordotic gait. Can't increase walking speed. 4. Moderately adapted gait. Can pick up speed but can't run. 5. Able to pick up speed but runs with a double stance phase, i.e., cannot achieve both feet off the ground. 6. Runs and gets both feet off the ground (with no double stance phase). The higher the grade, the better the outcome.
| sec | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Time Function Test (TFT): Time to Walk/Run 10 Meters | 0.013 (-0.100 to 0.125) | 0.078 (-0.072 to 0.228) |
TFT is assessed through 3 parameters, one of which is "time to climb 4 standard steps". The patient was asked to stand at the bottom of the stairs with his arms by his sides. At the "go" signal, he/she had to walk up the stairs as quickly and safely as possible (using handrails if needed) until reaching an erect position on the top stair. The stair climb speed was calculated as 4/time in seconds taken to climb the 4 standard stairs. Grading of the 4-step ascent was:1. Unable to climb 4 stairs.2. Climbs 4 stairs "marking time" (climbs one foot at a time with both feet on a step before moving to next step), using both arms on one or both handrails.3. Climbs 4 stairs "marking time" (idem as up), using one arm on one handrail.4. Climbs 4 stairs "marking time" (idem as up), not needing handrail.5. Climbs 4 stairs alternating feet, needs handrail for support.6. Climbs 4 stairs alternating feet, not needing handrail support.The higher the grade, the better the outcome.
| sec | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Time Function Test (TFT) Via Time to Climb 4 Standard Steps | -0.144 (-0.339 to 0.051) | -0.123 (-0.396 to 0.149) |
Time function test (TFT) is assessed through 3 different parameters, one of which was "time to rise from the floor". The patient started the test lying on his back with arms at his sides and was asked to get up as quickly as possible. The rise from floor velocity was calculated as 1/time in seconds taken to stand up. Grading was as follows: 1. Unable to stand, even with use of a chair. 2. Assisted Gowers' sign - requires furniture to assist in rising to full upright posture. 3. Full Gowers' sign - rolls over, stands up with both hands "climbing up" the legs to achieve full upright posture. 4. Half Gowers' sign - rolls over, stands up with one hand support on leg. 5. Rolls to the side and/or stands up with one hand or both hands on the floor to start to rise up but does not touch legs. 6. Stands up without rolling over or using hands. The higher the grade, the better the outcome.
| sec | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Time Function Test Via Time to Rise From Floor | 1.392 (-0.968 to 3.753) | 0.774 (-3.014 to 4.562) |
The 6-minute walk/run test (6MWT) assessed the distance walked in 6 minutes. The 6MWT was performed indoors on a flat, smooth path, at least 30 m long and 3 m wide, with a cone at each end around which the patient had to walk. Six progressively numbered markers were used to mark the distance travelled at each minute. Five progressively lettered markers were used to indicate any falls. Two staff members were present during the test; the physiotherapist, to give the patient instructions, and a staff member who followed the patient giving encouragements. The patient was instructed to go from cone to cone as fast as he could but without running, and that he could stop to rest whenever he/she wanted. The time walked, distance walked after each minute, time of each fall and distance walked before each fall were registered. A summary of the 6-minute maximum distance walked/run after 12 months of treatment is reported in minutes.
| log [meters] | Givinostat | Placebo |
|---|---|---|
| Change From Baseline to Visit 11 in Distance Performed Via 6-minute Walk/Run Test (6MWT, Expressed as Log Least Square Mean) | -0.058 (-0.118 to 0.002) | -0.046 (-0.128 to 0.036) |
Percentage of patients with \< 10% worsening in 6-Minute Walking Test after 12 months of treatment with Givinostat comparing to placebo patients.
| Participants | Givinostat | Placebo |
|---|---|---|
| Percentage of Patients With < 10% Worsening in 6MWT After 12 Months of Treatment. | 7 | 1 |
Percentage of patients losing the ability to ambulate from baseline to the end of study (Visit 11 or Month 12)
| Participants | Givinostat | Placebo |
|---|---|---|
| Count of Participant Who Lose Ambulation During the Study (From Baseline to Month 12) | 0 | 0 |
A summary of the number of patients who fell and the number of falls occurring during the 6MWT is shown.
| Participants | Givinostat | Placebo |
|---|---|---|
| Percentage of Patients Who Fell During the 6MWT | 1 | 1 |
Evaluation was performed by mean left and right knee extension, mean left and right elbow flexion using the Hand Held Myometry (HHM). Using it, the muscle strength of the knee extensor and elbow flexor were measured via standardized procedures; 3 measurements were recorded from each muscle group on each side. The mean of the 3 measurements was calculated. Knee Extension: the pt was sitting, pelvis and knee at a 90° angle. His/her feet were above the ground with the femur in neutral rotation. He/she could hold on to the edge of the bed/chair and, in case, additional stabilization was provided at the distal third of the thigh, just above the knee. The HHM was placed on the anterior surface of the lower third of the tibia, proximal to the ankle joint. Elbow flexion: pt lying on his back, arm by his side, elbow flexed at a 90° angle, forearm in supine position. The MMH was placed between the middle and distal third of the forearm, proximal to the radial styloid process.
| Newton | Givinostat | Placebo |
|---|---|---|
| Left Knee Extension (N) | -1.479 (-10.208 to 7.251) | -5.051 (-15.952 to 5.851) |
| Right Knee Extension (N) | 0.703 (-5.212 to 6.618) | -0.460 (-7.705 to 6.784) |
| Left Elbow Flexion (N) | 1.551 (-10.046 to 13.148) | -2.373 (-17.487 to 12.742) |
| Right Elbow Flexion (N) | -1.277 (-13.384 to 10.830) | -5.381 (-21.270 to 10.508) |
A summary of QoL (SF-36, Single items Short Form survey) in the ITT set is shown. QoL (SF-36) is assessed considering: * Physical Functioning (PF) * Role-Physical (RP) * Bodily Pain (BP) * General Health (GH) * Vitality (VT) * Social Functioning (SF) * Role-Emotional (RE) * Mental Health (MH) * Physical Component Summary (PCS) * Mental Component Summary (MCS) The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score, the greater the disability. The SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and are widely utilized by managed care organizations for routine monitoring and assessment of care outcomes in adult patients.
| units on a scale | Givinostat | Placebo |
|---|---|---|
| Physical Functioning | -1.03 ± 16.274 | -5.00 ± 11.989 |
| Role-Physical | -2.21 ± 19.697 | 0.37 ± 16.006 |
| Bodily Pain | 5.12 ± 19.384 | 2.12 ± 15.227 |
| General Health | 0.82 ± 14.532 | 1.47 ± 13.267 |
| Vitality | 0.55 ± 11.654 | 3.68 ± 12.705 |
| Social Functioning | 2.94 ± 22.415 | 8.82 ± 20.139 |
| Role-Emotional | 0.00 ± 20.205 | 4.90 ± 15.607 |
| Mental Health | 4.12 ± 15.997 | 4.41 ± 13.793 |
| Physical Component Summary | -0.17 ± 5.633 | -1.20 ± 5.535 |
| Mental Component Summary | 1.41 ± 7.345 | 3.70 ± 7.177 |
Treatment-emergent adverse events (TEAEs) are defined as those events with an onset date after study treatment initiation. An AE is an untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. A serious AE is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
| Participants | Givinostat | Placebo |
|---|---|---|
| Number of patients with any TEAEs | 30 | 9 |
| Number of patients with serious TEAEs | 0 | 0 |
| Number of patients with TEAEs leading to interruption of study treatment | 11 | 1 |
| Number of patients with fatal TEAEs | 0 | 0 |
| Number of patients with mild TEAEs | 30 | 9 |
| Number of patients with moderate TEAEs | 12 | 1 |
| Number of patients with severe TEAEs | 5 | 0 |
| Number of patients with TEAEs related to study treatment | 29 | 4 |
| Number of patients with TEAEs not related to study treatment | 25 | 8 |
Evaluation was performed comparing Dixon Magnetic Resonance Imaging (MRI) before and after 12 months of treatment with Givinostat versus placebo. The lower limb muscles assessed were: whole thigh, quadriceps, medial thigh, hamstrings, triceps surae and pelvic girdle. Please note that statistics data are expressed as: Least Square Means (95% CI) for whole thigh, quadriceps, hamstrings, triceps surae and pelvis girdle; while as Log Least Square Means (95% CI) for medial thigh.
| log[percentage of fat in muscle] | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in the Percentage of Fat Fraction of Lower Limb Muscles (Log) | 0.012 (-0.017 to 0.041) | 0.038 (0.003 to 0.073) |
A summary of mean change in the contractile area of lower limb muscles comparing MRI findings before and after 12 months of treatment in the ITT set is reported. The lower limb muscles considered are the same as the outcome 3. Please note that statistic data are expressed as Least Square Means (95% CI) except for Hamstrings which is expressed as Log Least Square Means.
| centimeters^2 | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Contractile Area of Lower Limb Muscles (MRI) (Log) | 0.025 (-0.042 to 0.092) | -0.022 (-0.104 to 0.059) |
A summary of the mean change in cross-sectional area (CSA) by type after 12 months of treatment in the ITT set is reported. Please note that descriptive statistic data are expressed as Log Least Square Means (95% CI) for CSA type I fibers, and as Least Square Means (95% CI) for CSA type II fibers and Total CSA.
| log [micrometers^2] | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline to Visit 11 in Biopsy Histology Parameters: CSA by Type (I or II Fibers), Total CSA (Log) | 0.255 (-0.069 to 0.579) | 0.246 (-0.166 to 0.658) |
Evaluation of histologic parameters such as Fiber with nuclear centralizations (%), Total number of fibers (%), and Regenerative fibers (%) were performed comparing muscle biopsies after 12 months of treatment with Givinostat. Please note that descriptive statistic data are expressed as log least square mean for Regenerative fibers (%), and total number of fibers (Slides I), while are expressed as least square mean for Fibers with nuclear centralizations (%) and total number of fibers (Slides II and III).
| log[percentage of fibers] | Givinostat | Placebo |
|---|---|---|
| Total number of fibers (Slide I) | -0.207 (-0.446 to 0.032) | -0.257 (-0.552 to 0.037) |
| Regenerative fibers | 0.667 (-0.031 to 1.365) | 1.104 (0.248 to 1.961) |
Collected over Throughout the study, from screening (visits 1 and 2) to EOS/early withdrawal (V11, at week 48 ± 7 days) till follow-up visit (visit 12, at week 52 ± 7 days). This means the AEs were monitored from screening to day 364 ± 7.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Givinostat | 0/34 (0%) | 0/34 (0%) | 30/34 (88.2%) |
| Placebo | 0/17 (0%) | 0/17 (0%) | 9/17 (52.9%) |
| Event | Givinostat | Placebo |
|---|---|---|
| Platelet count decreasedInvestigations | 17/34 | 0/17 |
| DiarrhoeaGastrointestinal disorders | 16/34 | 0/17 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 10/34 | 1/17 |
| FallInjury, poisoning and procedural complications | 2/34 | 2/17 |
| Ligament sprainInjury, poisoning and procedural complications | 4/34 | 1/17 |
| Blood triglycerides increasedInvestigations | 4/34 | 1/17 |
| Abdominal pain upperGastrointestinal disorders | 3/34 | 1/17 |
| DyspepsiaGastrointestinal disorders | 3/34 | 1/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/34 | 0/17 |
| Sinus tachycardiaCardiac disorders | 0/34 | 1/17 |
Intent-To-Treat Analysis (ITT) Set: all patients assigned treatment by randomization who received at least one dose of study medication. According to the intent to treat principle, patients were analyzed according to the treatment assigned. Efficacy analyses were performed on the ITT set.
| Age, Categorical(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 17 | 51 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Givinostat | Placebo | Total |
|---|---|---|---|
| Mean | 36.5 ± 11.56 | 39.2 ± 9.84 | 37.4 ± 10.99 |
| Sex: Female, Male(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 34 | 17 | 51 |
| Race (NIH/OMB)(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 17 | 18 |
| White | 33 | 0 | 33 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| Netherlands | 3 | 3 | 6 |
| Italy | 31 | 14 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Mar 2021, 38 months.
Results were first posted in Nov 2024, 3 years 7 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 38 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat
Muscular Dystrophy, Duchenne →